HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Artaza, J. N Articles by Gonzalez-Cadavid, N. F Search for Related Content PubMed PubMed Citation Articles by Artaza, J. N Articles by Gonzalez-Cadavid, N. F

¹ Division of Endocrinology Metabolism and Molecular Medicine and RCMI Molecular Core² Department of Biomedical Sciences, The Charles R Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, California, 90059 USA³ Department of Urology UCLA David Geffen School of Medicine, Los Angeles, California, 90095 USA

(Correspondence should be addressed to J N Artaza at the Division of Endocrinology, Metabolism and Molecular Medicine, Charles Drew University of Medicine and Science; Email: jorgeartaza{at}cdrewu.edu)

Tissue fibrosis, the excessive deposition of collagen/extracellular matrix combined with the reduction of the cell compartment, defines fibroproliferative diseases, a major cause of death and a public health burden. Key cellular processes in fibrosis include the generation of myofibroblasts from progenitor cells, and the activation or switch of already differentiated cells to a fibrotic synthetic phenotype. Myostatin, a negative regulator of skeletal muscle mass, is postulated to be involved in muscle fibrosis. We have examined whether myostatin affects the differentiation of a multipotent mesenchymal mouse cell line into myofibroblasts, and/or modulates the fibrotic phenotype and Smad expression of the cell population. In addition, we investigated the role of follistatin in this process. Incubation of cells with recombinant myostatin protein did not affect the proportion of myofibroblasts in the culture, but significantly upregulated the expression of fibrotic markers such as collagen and the key profibrotic factors transforming growth factor-β1 (TGF-β1) and plasminogen activator inhibitor (PAI-1), as well as Smad3 and 4, and the pSmad2/3. An antifibrotic process evidenced by the upregulation of follistatin, Smad7, and matrix metalloproteinase 8 accompanied these changes. Follistatin inhibited TGF-β1 induction by myostatin. Transfection with a cDNA expressing myostatin upregulated PAI-1, whereas an shRNA against myostatin blocked this effect. In conclusion, myostatin induced a fibrotic phenotype without significantly affecting differentiation into myofibroblasts. The concurrent endogenous antifibrotic reaction confirms the view that phenotypic switches in multipotent and differentiated cells may affect the progress or reversion of fibrosis, and that myostatin pharmacological inactivation may be a novel therapeutic target against fibrosis.

This article has been cited by other articles:

				R. Vettor, G. Milan, C. Franzin, M. Sanna, P. De Coppi, R. Rizzuto, and G. Federspil The origin of intermuscular adipose tissue and its pathophysiological implications Am J Physiol Endocrinol Metab, November 1, 2009; 297(5): E987 - E998. [Abstract] [Full Text] [PDF]

				S. Welle, A. Cardillo, M. Zanche, and R. Tawil Skeletal muscle gene expression after myostatin knockout in mature mice Physiol Genomics, August 7, 2009; 38(3): 342 - 350. [Abstract] [Full Text] [PDF]

				J. N Artaza and K. C Norris Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells J. Endocrinol., February 1, 2009; 200(2): 207 - 221. [Abstract] [Full Text] [PDF]